A newly published paper in Nature shows how bacteria hijack crosstalk between nerve and immune cells to cause meningitis. In the paper, a team led by researchers at Harvard Medical School details the step-by-step cascade that allows bacteria to break through the brain’s protective layers—the meninges—and cause meningitis, a highly fatal disease.

“We’ve identified a neuroimmune axis at the protective borders of the brain that is hijacked by bacteria to cause infection—a clever maneuver that ensures bacterial survival and leads to widespread disease,” said study senior author Isaac Chiu.

The study identifies two central players in this molecular chain of events that leads to infection—a chemical released by nerve cells and an immune cell receptor blocked by the chemical. The study also revealed that blocking either one can interrupt the cascade and thwart the bacterial invasion.  

The team focused on two pathogens—Streptococcus pneumoniae and Streptococcus agalactiae, leading causes of bacterial meningitis in humans. In a series of experiments, they found that when bacteria reach the meninges, the pathogens trigger a chain of events that culminates in disseminated infection.

Search Antibodies
Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.

First, it was discovered that bacteria release a toxin that activates pain neurons in the meninges. The activation of pain neurons by bacterial toxins, the researchers noted, could explain the severe, intense headache that is a hallmark of meningitis. Next, the activated neurons release a signaling chemical called CGRP, which attaches to an immune-cell receptor called RAMP1. RAMP1 is particularly abundant on the surface of macrophages. 

Once the chemical engages the receptor, the immune cell is effectively disabled. Under normal conditions, as soon as macrophages detect the presence of bacteria, they spring into action to attack, destroy, and engulf them. Macrophages also send distress signals to other immune cells to provide a second line of defense. The team’s experiments showed that when CGRP gets released and attaches to the RAMP1 receptor on macrophages, it prevented these immune cells from recruiting help from fellow immune cells. As a result, the bacteria proliferated and caused widespread infection.

To confirm that the bacterially induced activation of pain neurons was the critical first step in disabling the brain’s defenses, the researchers checked what would happen to infected mice lacking pain neurons.  Mice without pain neurons developed less severe brain infections when infected with two types of bacteria known to cause meningitis. The meninges of these mice, the experiments showed, had high levels of immune cells to combat the bacteria. By contrast, the meninges of mice with intact pain neurons showed meager immune responses and far fewer activated immune cells, demonstrating that neurons get hijacked by bacteria to subvert immune protection.

To confirm that CGRP was, indeed, the activating signal, researchers compared the levels of CGRP in meningeal tissue from infected mice with intact pain neurons and meningeal tissue from mice lacking pain neurons. The brain cells of mice lacking pain neurons had barely detectable levels of CGRP and few signs of bacterial presence. By contrast, meningeal cells of infected mice with intact pain neurons showed markedly elevated levels of both CGRP and more bacteria.

In another experiment, the researchers used a chemical to block the RAMP1 receptor, preventing it from communicating with CGRP, the chemical released by activated pain neurons. The RAMP1 blocker worked both as preventive treatment before infection and as a treatment once infection had occurred.  Mice pretreated with RAMP1 blockers showed reduced bacterial presence in the meninges. Likewise, mice that received RAMP1 blockers several hours after infection and regularly thereafter had milder symptoms and were more capable of clearing bacteria, compared with untreated animals.

The experiments suggest drugs that block either CGRP or RAMP1 could allow immune cells to do their job properly and increase the brain’s border defenses. Compounds that block CGRP and RAMP1 are found in widely used drugs to treat migraine, a condition believed to originate in the top meningeal layer, the dura mater. Could these compounds become the basis for new medicines to treat meningitis? It’s a question the researchers say merits further investigation.